Do analysts prefer DTSS or ENGN?

enGene has a consensus price target of $12.68, indicating a potential upside of 692.61%. Given enGene's stronger consensus rating and higher possible upside, analysts plainly believe enGene is more favorable than Datasea. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Datasea 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 enGene 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21

Which has preferable earnings and valuation, DTSS or ENGN?

Datasea has higher revenue and earnings than enGene. Datasea is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Datasea $71.62M 0.14 -$5.09M -$0.32 N/A enGene N/A N/A -$117.30M -$2.25 N/A

Is DTSS or ENGN more profitable?

enGene has a net margin of 0.00% compared to Datasea's net margin of -4.80%. enGene's return on equity of -55.83% beat Datasea's return on equity. Company Net Margins Return on Equity Return on Assets Datasea -4.80% -88.98% -37.33% enGene N/A -55.83% -45.74%

Which has stronger valuation and earnings, ENGN or PRTA?

enGene has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.25 N/A Prothena $9.68M 42.78 -$244.09M -$2.82 N/A

Is ENGN or PRTA more profitable?

enGene has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -55.83% -45.74% Prothena -260.92% -43.44% -36.87%

Does the media refer more to ENGN or PRTA?

In the previous week, enGene had 8 more articles in the media than Prothena. MarketBeat recorded 14 mentions for enGene and 6 mentions for Prothena. Prothena's average media sentiment score of 1.39 beat enGene's score of 0.09 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ENGN or EOLS?

Evolus has higher revenue and earnings than enGene. Evolus is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.25 N/A Evolus $297.18M 1.49 -$51.64M -$0.67 N/A

Is ENGN or EOLS more profitable?

enGene has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -55.83% -45.74% Evolus -14.39% N/A -19.03%

Does the media refer more to ENGN or EOLS?

In the previous week, enGene had 12 more articles in the media than Evolus. MarketBeat recorded 14 mentions for enGene and 2 mentions for Evolus. Evolus' average media sentiment score of 1.40 beat enGene's score of 0.09 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Evolus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, IMMX or ENGN?

Immix Biopharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.92 N/A enGene N/A N/A -$117.30M -$2.25 N/A

Is IMMX or ENGN more profitable?

enGene's return on equity of -55.83% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% enGene N/A -55.83% -45.74%

Do analysts rate AVTE or ENGN?

enGene has a consensus target price of $12.68, indicating a potential upside of 692.61%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 enGene 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21

Which has higher earnings and valuation, AVTE or ENGN?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A enGene N/A N/A -$117.30M -$2.25 N/A

Is AVTE or ENGN more profitable?

enGene's return on equity of -55.83% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% enGene N/A -55.83% -45.74%

enGene (ENGN) Competitors

$1.60 -0.07 (-4.19%)

Closing price 04:00 PM Eastern

Extended Trading

$1.63 +0.03 (+1.62%)

As of 05:16 PM Eastern

Compare

ENGN vs. DTSS, PRTA, EOLS, IMMX, and AVTE

Should you buy enGene stock or one of its competitors? MarketBeat compares enGene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with enGene include Datasea (DTSS), Prothena (PRTA), Evolus (EOLS), Immix Biopharma (IMMX), and Aerovate Therapeutics (AVTE).

How does enGene compare to Datasea?

Datasea (NASDAQ:DTSS) and enGene (NASDAQ:ENGN) are related small-cap companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

82.1% of Datasea shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 50.7% of Datasea shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, enGene had 13 more articles in the media than Datasea. MarketBeat recorded 14 mentions for enGene and 1 mentions for Datasea. Datasea's average media sentiment score of 1.89 beat enGene's score of 0.09 indicating that Datasea is being referred to more favorably in the media.

Company	Overall Sentiment
Datasea	Very Positive
enGene	Neutral

Datasea has higher revenue and earnings than enGene. Datasea is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Datasea	$71.62M	0.14	-$5.09M	-$0.32	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

enGene has a consensus price target of $12.68, indicating a potential upside of 692.61%. Given enGene's stronger consensus rating and higher possible upside, analysts plainly believe enGene is more favorable than Datasea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Datasea	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

enGene has a net margin of 0.00% compared to Datasea's net margin of -4.80%. enGene's return on equity of -55.83% beat Datasea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Datasea	-4.80%	-88.98%	-37.33%
enGene	N/A	-55.83%	-45.74%

Datasea has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, enGene has a beta of -0.3, indicating that its stock price is 130% less volatile than the broader market.

Summary

Datasea beats enGene on 8 of the 15 factors compared between the two stocks.

How does enGene compare to Prothena?

enGene (NASDAQ:ENGN) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

enGene presently has a consensus target price of $12.68, indicating a potential upside of 692.61%. Prothena has a consensus target price of $23.75, indicating a potential upside of 200.25%. Given enGene's higher probable upside, research analysts clearly believe enGene is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Prothena	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

enGene has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
Prothena	$9.68M	42.78	-$244.09M	-$2.82	N/A

In the previous week, enGene had 8 more articles in the media than Prothena. MarketBeat recorded 14 mentions for enGene and 6 mentions for Prothena. Prothena's average media sentiment score of 1.39 beat enGene's score of 0.09 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.2% of enGene shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 10.5% of enGene shares are held by company insiders. Comparatively, 10.4% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

enGene has a beta of -0.3, indicating that its share price is 130% less volatile than the broader market. Comparatively, Prothena has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

enGene has a net margin of 0.00% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
Prothena	-260.92%	-43.44%	-36.87%

Summary

Prothena beats enGene on 8 of the 15 factors compared between the two stocks.

How does enGene compare to Evolus?

enGene (NASDAQ:ENGN) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

64.2% of enGene shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 5.0% of Evolus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

enGene currently has a consensus price target of $12.68, indicating a potential upside of 692.61%. Evolus has a consensus price target of $16.00, indicating a potential upside of 138.10%. Given enGene's higher possible upside, analysts plainly believe enGene is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

enGene has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
Evolus	-14.39%	N/A	-19.03%

Evolus has higher revenue and earnings than enGene. Evolus is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
Evolus	$297.18M	1.49	-$51.64M	-$0.67	N/A

In the previous week, enGene had 12 more articles in the media than Evolus. MarketBeat recorded 14 mentions for enGene and 2 mentions for Evolus. Evolus' average media sentiment score of 1.40 beat enGene's score of 0.09 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evolus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

enGene has a beta of -0.3, indicating that its share price is 130% less volatile than the broader market. Comparatively, Evolus has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market.

Summary

Evolus beats enGene on 9 of the 14 factors compared between the two stocks.

How does enGene compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Immix Biopharma presently has a consensus target price of $19.50, indicating a potential upside of 138.39%. enGene has a consensus target price of $12.68, indicating a potential upside of 692.61%. Given enGene's higher possible upside, analysts plainly believe enGene is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Immix Biopharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

enGene's return on equity of -55.83% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
enGene	N/A	-55.83%	-45.74%

Immix Biopharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, enGene has a beta of -0.3, suggesting that its stock price is 130% less volatile than the broader market.

In the previous week, enGene had 13 more articles in the media than Immix Biopharma. MarketBeat recorded 14 mentions for enGene and 1 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.87 beat enGene's score of 0.09 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Immix Biopharma	Very Positive
enGene	Neutral

Summary

Immix Biopharma and enGene tied by winning 6 of the 12 factors compared between the two stocks.

How does enGene compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

enGene has a consensus target price of $12.68, indicating a potential upside of 692.61%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

enGene's return on equity of -55.83% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
enGene	N/A	-55.83%	-45.74%

In the previous week, enGene had 14 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 14 mentions for enGene and 0 mentions for Aerovate Therapeutics. enGene's average media sentiment score of 0.09 beat Aerovate Therapeutics' score of 0.00 indicating that enGene is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
enGene	Neutral

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, enGene has a beta of -0.3, meaning that its share price is 130% less volatile than the broader market.

64.2% of enGene shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

enGene beats Aerovate Therapeutics on 9 of the 13 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENGN vs. The Competition

Export

Metric	enGene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$111.86M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-0.71	10.45	20.85	21.87
Price / Sales	N/A	290.84	500.87	105.21
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	0.62	8.00	10.43	6.70
Net Income	-$117.30M	$23.89M	$3.56B	$337.26M
7 Day Performance	-4.19%	-3.49%	-1.39%	-1.41%
1 Month Performance	6.67%	1.03%	0.86%	1.15%
1 Year Performance	-50.16%	34.39%	19.42%	22.61%

enGene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENGN enGene	3.6586 of 5 stars	$1.60 -4.2%	$12.68 +692.6%	-50.1%	$111.86M	N/A	N/A	31	Upcoming Earnings
DTSS Datasea	1.3698 of 5 stars	$0.92 +5.3%	N/A	-61.2%	$9.61M	$71.62M	N/A	120	Positive News High Trading Volume
PRTA Prothena	2.948 of 5 stars	$8.47 -1.1%	$23.75 +180.4%	+61.3%	$443.43M	$57.94M	N/A	130	Positive News
EOLS Evolus	2.811 of 5 stars	$6.70 +0.3%	$16.00 +138.8%	-30.6%	$441.26M	$297.18M	N/A	170	Positive News
IMMX Immix Biopharma	3.4253 of 5 stars	$8.01 +1.8%	$19.50 +143.4%	+242.3%	$435.83M	N/A	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENGN) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enGene (ENGN) Competitors